These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 26215948)

  • 1. Reply to K. Lu.
    Morris MJ
    J Clin Oncol; 2015 Oct; 33(28):3222-3. PubMed ID: 26215948
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to K. Lu.
    Fizazi K; Dreicer R
    J Clin Oncol; 2015 Oct; 33(28):3222. PubMed ID: 26215954
    [No Abstract]   [Full Text] [Related]  

  • 3. The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel?
    Lu K
    J Clin Oncol; 2015 Oct; 33(28):3221. PubMed ID: 26215959
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostate cancer: CYP17A1 inhibitor failure-lessons for future drug development.
    Sharifi N
    Nat Rev Urol; 2015 May; 12(5):245-6. PubMed ID: 25823374
    [No Abstract]   [Full Text] [Related]  

  • 5. Failure of ELM-PC 5: an ineffective drug or an unfit end point?
    Morris MJ
    J Clin Oncol; 2015 Mar; 33(7):679-81. PubMed ID: 25646190
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) plus Prednisone with Placebo plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer that has Progressed during or after Docetaxel-Based Therapy: ELM-PC 5.
    Taneja SS
    J Urol; 2015 Oct; 194(4):990. PubMed ID: 26382777
    [No Abstract]   [Full Text] [Related]  

  • 7. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5.
    Fizazi K; Jones R; Oudard S; Efstathiou E; Saad F; de Wit R; De Bono J; Cruz FM; Fountzilas G; Ulys A; Carcano F; Agarwal N; Agus D; Bellmunt J; Petrylak DP; Lee SY; Webb IJ; Tejura B; Borgstein N; Dreicer R
    J Clin Oncol; 2015 Mar; 33(7):723-31. PubMed ID: 25624429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
    Shiota M; Yokomizo A; Adachi T; Koga H; Yamaguchi A; Imada K; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Naito S
    Jpn J Clin Oncol; 2014 Sep; 44(9):860-7. PubMed ID: 24951829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
    Mikah P; Krabbe LM; Eminaga O; Herrmann E; Papavassilis P; Hinkelammert R; Semjonow A; Schrader AJ; Boegemann M
    BMC Cancer; 2016 Mar; 16():214. PubMed ID: 26975660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prediction of unplanned discontinuation of treatment in patients with castration-resistant prostate cancer-results from the IBuTu study].
    Honecker F; Wedding U; Kallischnigg G; Schroeder A; Klier J; Frangenheim T; Weißbach L
    Urologe A; 2018 Aug; 57(8):909-918. PubMed ID: 29978302
    [No Abstract]   [Full Text] [Related]  

  • 11. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Han KS; Hong SJ
    Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on "Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer".
    Chueh SC
    South Med J; 2015 Apr; 108(4):229. PubMed ID: 25871993
    [No Abstract]   [Full Text] [Related]  

  • 13. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
    Wilkerson J; Abdallah K; Hugh-Jones C; Curt G; Rothenberg M; Simantov R; Murphy M; Morrell J; Beetsch J; Sargent DJ; Scher HI; Lebowitz P; Simon R; Stein WD; Bates SE; Fojo T
    Lancet Oncol; 2017 Jan; 18(1):143-154. PubMed ID: 27979599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Making progress on progression in metastatic prostate cancer.
    Armstrong AJ; Halabi S
    J Clin Oncol; 2015 Apr; 33(12):1322-4. PubMed ID: 25667271
    [No Abstract]   [Full Text] [Related]  

  • 15. Prostate cancer: Clinical implications of therapeutic sequence in mCRPC.
    Vaishampayan U
    Nat Rev Urol; 2015 Jan; 12(1):13-4. PubMed ID: 25403243
    [No Abstract]   [Full Text] [Related]  

  • 16. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment].
    Basset V; Flamand V; Crouzet S; Ploussard G
    Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients.
    Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; Vermeulen A; Poggesi I; Nandy P
    Clin Cancer Res; 2015 Jul; 21(14):3170-7. PubMed ID: 25829400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H
    Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recruiting participants - study of therapy of CRPC].
    Aktuelle Urol; 2014 Sep; 45(5):354-5. PubMed ID: 25275687
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer.
    Perletti G
    Arch Ital Urol Androl; 2016 Mar; 88(1):74-5. PubMed ID: 27072185
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.